CPI Logo-Color.png
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
February 24, 2021 07:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
February 18, 2021 10:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
CPI Logo-Color.png
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
January 07, 2021 09:30 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...
CPI Logo-Color.png
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 06, 2021 10:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P....
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
October 29, 2020 07:00 ET | Constellation Pharmaceuticals , Inc.
MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
October 19, 2020 14:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
CPI Logo-Color.png
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
June 12, 2019 09:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey, Senior Scientist at Constellation Pharmaceuticals,...
CPI Logo-Color.png
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference
November 15, 2018 07:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial Results
August 14, 2018 16:15 ET | Constellation Pharmaceuticals , Inc.
Company raises an aggregate of $160 million in crossover financing in April and initial public offering (IPO) in JulyCompany progressing its pipeline, including clinical programs CPI-1205 and CPI-0610...
Constellation Pharmaceuticals Announces Pricing of Initial Public Offering
July 18, 2018 19:56 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”)(Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...